BPCR vs. TV2H, KLSO, KRM, ADA, WCW, LFI, NBDG, ALGW, WINV, and TFG
Should you be buying BioPharma Credit stock or one of its competitors? The main competitors of BioPharma Credit include Thames Ventures VCT 2 Healthcare Shs (TV2H), Kelso Group (KLSO), KRM22 (KRM), Adams (ADA), Walker Crips Group (WCW), London Finance & Investment Group (LFI), NB Distressed Debt New Glb (NBDG), Alpha Growth (ALGW), Worsley Investors (WINV), and Tetragon Financial (TFG). These companies are all part of the "asset management" industry.
Thames Ventures VCT 2 Healthcare Shs (LON:TV2H) and BioPharma Credit (LON:BPCR) are both small-cap financial services companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, dividends and community ranking.
In the previous week, BioPharma Credit's average media sentiment score of 0.00 equaled Thames Ventures VCT 2 Healthcare Shs'average media sentiment score.
BioPharma Credit has higher revenue and earnings than Thames Ventures VCT 2 Healthcare Shs. Thames Ventures VCT 2 Healthcare Shs is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.
38.7% of BioPharma Credit shares are held by institutional investors. 0.1% of Thames Ventures VCT 2 Healthcare Shs shares are held by insiders. Comparatively, 7.8% of BioPharma Credit shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
BioPharma Credit received 84 more outperform votes than Thames Ventures VCT 2 Healthcare Shs when rated by MarketBeat users.
BioPharma Credit has a net margin of 83.84% compared to BioPharma Credit's net margin of 0.00%. Thames Ventures VCT 2 Healthcare Shs' return on equity of 13.65% beat BioPharma Credit's return on equity.
Thames Ventures VCT 2 Healthcare Shs pays an annual dividend of GBX 1 per share and has a dividend yield of 2.1%. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 795.5%. Thames Ventures VCT 2 Healthcare Shs pays out -5,000.0% of its earnings in the form of a dividend. BioPharma Credit pays out 5,384.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Summary
BioPharma Credit beats Thames Ventures VCT 2 Healthcare Shs on 10 of the 11 factors compared between the two stocks.
Get BioPharma Credit News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioPharma Credit Competitors List
Related Companies and Tools
